Serina Therapeutics launched a corporate communications platform to enhance stakeholder engagement and provide updates on their Parkinson’s disease program.
Quiver AI Summary
Serina Therapeutics, Inc., a clinical-stage biotechnology company, has launched a new corporate communications platform aimed at providing transparent updates to various stakeholders, including patients, clinicians, investors, and the scientific community. This initiative features regular digital updates, educational resources, multimedia content, and expert commentary, particularly in light of the upcoming trial for SER-252, an investigational therapy for Parkinson's disease. The SER-252-1b trial will assess the safety and efficacy of the drug, which aims to improve motor functions in patients through a novel delivery system. This communications effort is designed to complement Serina’s ongoing clinical activities and enhance engagement with the community as they work towards developing new treatments for serious conditions.
Potential Positives
- Launch of a comprehensive corporate communications platform enhances transparency and accessibility of information for stakeholders, which can improve relationships with patients, clinicians, and investors.
- The new platform is set to provide regular updates and educational resources, demonstrating Serina's commitment to keeping the scientific community informed about its advancements and clinical trials.
- The initiation of the SER-252 trial in Parkinson’s disease marks a significant step in the development pipeline, potentially leading to new treatment options for patients with serious conditions.
- Collaboration with Enable Injections to leverage the enFuse™ wearable drug delivery platform improves patient comfort, enhancing the administration of SER-252 therapy.
Potential Negatives
- Announcement of a communications platform may indicate a need to improve transparency and address previous concerns about communication with stakeholders.
- The upcoming trial of SER-252 is categorized as a Phase 1b study, which may indicate that the drug is still in very early stages of development and may face significant hurdles ahead.
- There is no mention of successful prior trials or data supporting the efficacy of SER-252, which may raise skepticism among stakeholders regarding its potential as a treatment.
FAQ
What is the new communications platform from Serina Therapeutics?
Serina's new platform delivers timely updates, educational resources, and expert commentary for patients, clinicians, investors, and the scientific community.
How will Serina support engagement with stakeholders?
The platform will provide opportunities for webinars and online forums to foster dialogue with patient and professional communities.
What is SER-252 and its purpose?
SER-252 is an investigational therapy designed to offer continuous dopaminergic stimulation for advanced Parkinson’s patients, aiding in motor fluctuations.
What are the goals of the SER-252 clinical trial?
The SER-252 trial aims to evaluate safety, tolerability, pharmacokinetics, and exploratory efficacy in adults with Parkinson’s disease.
How does Serina's POZ Platform™ enhance drug therapies?
The POZ Platform™ aims to improve efficacy and safety profiles across various drug modalities, including small molecules and RNA therapeutics.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SER Insider Trading Activity
$SER insiders have traded $SER stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $SER stock by insiders over the last 6 months:
- RANDALL MOREADITH (Chief Scientific Officer) has made 0 purchases and 12 sales selling 99,674 shares for an estimated $618,271.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SER Hedge Fund Activity
We have seen 6 institutional investors add shares of $SER stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 85,290 shares (+130.5%) to their portfolio in Q2 2025, for an estimated $525,386
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 13,237 shares (+inf%) to their portfolio in Q2 2025, for an estimated $81,539
- CITADEL ADVISORS LLC removed 13,184 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $81,213
- MILLENNIUM MANAGEMENT LLC removed 10,721 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $66,041
- BLACKROCK, INC. added 8,706 shares (+283.9%) to their portfolio in Q2 2025, for an estimated $53,628
- HIGHTOWER ADVISORS, LLC removed 3,522 shares (-16.4%) from their portfolio in Q2 2025, for an estimated $21,695
- TOWER RESEARCH CAPITAL LLC (TRC) removed 912 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $5,617
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SER Analyst Ratings
Wall Street analysts have issued reports on $SER in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/28/2025
To track analyst ratings and price targets for $SER, check out Quiver Quantitative's $SER forecast page.
Full Release
HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today announced the launch of a comprehensive corporate communications platform designed to deliver timely, transparent updates to patients, clinicians, investors, and the broader scientific community.
The new initiative expands Serina’s direct channels of communication to provide stakeholders with clear, accessible information on the Company’s programs, regulatory progress, and scientific advances. The platform will feature regular digital updates, educational resources, multimedia content, and expert commentary from company leadership and scientific advisors.
“At Serina, we believe leadership in biotechnology requires not only advancing innovative science but also communicating that progress with clarity and transparency,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “As we prepare to initiate the planned trial of SER-252 in Parkinson’s disease, this new communications platform will serve as a vital resource for patients, clinicians, investors, and the broader scientific community. By providing timely updates and expert perspectives, we are ensuring that all stakeholders can follow our journey as we work to bring meaningful new treatment options to people living with Parkinson’s disease and other serious conditions.”
As part of the initiative, Serina plans to provide:
- Program and clinical updates delivered through the Company’s website and newsletters.
- Educational resources for physicians, patients, and scientists to better understand the potential of POZ-enabled therapeutics in improving therapeutic performance across multiple modalities.
- Multimedia content, including a new podcast series, to highlight perspectives from company leaders, investigators, and thought leaders in neuroscience and other therapeutic areas.
- Opportunities for engagement, including webinars and online forums to support dialogue with patient and professional communities.
This platform is designed to complement Serina’s ongoing clinical and regulatory activities, providing stakeholders with real-time access to relevant information as the Company advances its pipeline.
SER-252 Registrational Study Design Overview
The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b trial with single-ascending-dose (five cohorts of eight; n=40) and multiple-ascending-dose components (up to three cohorts of sixteen; n=48) in adults with Parkinson’s disease and motor fluctuations. The registrational study is designed to evaluate safety, tolerability, and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures that include MDS-UPDRS motor scores and structured motor-state assessments. Dose escalation will be overseen by a Safety Review Committee and the study will be conducted across sites in the U.S. and Australia.
About SER-252 (POZ-apomorphine)
SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS) via a single or twice-weekly subcutaneous injection. CDS has been shown to reduce the severity of motor fluctuations (which includes levodopa-induced dyskinesia) and enable greater daily on time, with reduced off time, in advanced Parkinson’s patients. SER-252 leverages strategic partner Enable Injections’ enFuse ™ wearable drug delivery platform to enhance patient comfort and convenience, providing CDS to patients via an easy-to-administer, long-acting subcutaneous injection.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform ™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatx.com .
For inquiries, please contact:
Stefan Riley
[email protected]
(256) 327-9630
